Search research articles
Contact Us
Filters
Showing results (61-70 of 161) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer, Paul Lorigan, Neil Steven, et al.
Molecular Cancer Therapeutics
|
December 16, 2014
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors
Kari L Kendra, Ruth Plummer, Ravi Salgia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
Cancer Treatment Reviews
|
January 4, 2024
Histology independent drug development - Is this the future for cancer drugs?
Lucinda Billingham, Lynn Brown, Theodor Framke, et al.
European Urology Oncology
|
August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Cancer Immunology, Immunotherapy : CII
|
June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Piotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.
British Journal of Cancer
|
June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Ruth Plummer, Divyanshu Dua, Nicola Cresti, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
The Oncologist
|
June 1, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
Melinda A Pruis, Matthew G Krebs, Ruth Plummer, et al.
British Journal of Cancer
|
May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
Aya El Helali, Ruth Plummer, Gordon C Jayson, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 161) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer, Paul Lorigan, Neil Steven, et al.
Molecular Cancer Therapeutics
|
December 16, 2014
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors
Kari L Kendra, Ruth Plummer, Ravi Salgia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer, Gerhardt Attard, Simon Pacey, et al.
Cancer Treatment Reviews
|
January 4, 2024
Histology independent drug development - Is this the future for cancer drugs?
Lucinda Billingham, Lynn Brown, Theodor Framke, et al.
European Urology Oncology
|
August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Cancer Immunology, Immunotherapy : CII
|
June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Piotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.
British Journal of Cancer
|
June 12, 2020
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Ruth Plummer, Divyanshu Dua, Nicola Cresti, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
The Oncologist
|
June 1, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
Melinda A Pruis, Matthew G Krebs, Ruth Plummer, et al.
British Journal of Cancer
|
May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours
Aya El Helali, Ruth Plummer, Gordon C Jayson, et al.
Page
of 17